A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components

NCT ID: NCT01780051

Last Updated: 2013-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2013-04-30

Brief Summary

This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after co-administration of Repaglinide 2mg and Metformin hydrochloride 500mg with administration of combination preparation of Repaglinide 2mg and Metformin hydrochloride 500mg in 50 healthy male volunteers.

Detailed Description

This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after co-administration of Repaglinide 2mg and Metformin hydrochloride 500mg with administration of combination preparation of Repaglinide 2mg and Metformin hydrochloride 500mg in 50 healthy male volunteers.

• All the subjects should be admitted one day prior to scheduled study date until 4pm to Chonbuk National University Hospital Clinical Trial Center and they will be served with the same dinner. After dinner, they should keep fast, they are just allowed to drink water until 8am of the study date.

• According to the randomly designated order, all subjects will be administrated with the study or reference products with 240mL of water at 9am(±2hours) on the first date of the study. The study or the reference products should be swallowed completely, and not to be chewed before swallowing.

• Study product : Repanorm M 2/500mg (Dalim BioTech Co., Ltd.)
• Reference products : Metformin HCl 500mg tablet, Repaglinide 2mg tablet

• Subjects have to fast for 4 hours post administration of the study or reference drugs(water intake is not allowed for 1 hour before and after the administration), and should follow standardized lunch after four hours and dinner 9 hours later from the time of administration

• Assessment and laboratory test will be performed in accordance with schedule written on the protocol

• After having 7 days of withdrawal period, the 2nd study period will be done at 9am(±2hours). In contrast of the 1st period, Sequence B which received the study product in 1st period will take the reference drugs for the 2nd period, while the group Sequence A which received reference drugs will take the study drug. The steps of administration of drugs and process of tests are the same with the 1st period

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequence A

Group Type: EXPERIMENTAL

Repaglinide/Metformin combination, Repaglinide, Metformin

Intervention Type: DRUG

Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.

Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2.

Sequence B

Group Type: EXPERIMENTAL

Repaglinide/Metformin combination, Repaglinide, Metformin

Intervention Type: DRUG

Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.

Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2.

Interventions

Repaglinide/Metformin combination, Repaglinide, Metformin

Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.

Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2.

Intervention Type: DRUG

Repaglinide/Metformin combination, Repaglinide, Metformin

Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.

Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy male volunteers ages between 20 and 55 years at screening

2. Subject with Body Mass Index(BMI) with the range of 17.5 to 30.5kg/m2 and body weight over 45kg

3. Signed informed consent with the date of signature

4. With ability to comply with all the scheduled visits, treatment plans; laboratory tests and other processes.

Exclusion Criteria

1. Positive of blood, kidney, endocrine, lung, gastro-intestinal, cardiovascular, hepatic, psychiatric, nervous, allergy; or with past and present disease history or symptoms that are clinically significant.

2. Any conditions that are likely to affect drug absorption. ex) gastrectomy

3. Positive on urine drug tests

4. History of drinking alcohol more than 12 ounces(360mL) of beer, 1.5 ounces(45mL) of liquor; or 21 drinks/week(1drink = 5 ounces(150mL) of wine ) 6months prior to screening

5. Participation in any other clinical studies within 2months prior to scheduled study drug administration

6. With Blood pressure of ≥ 160 mmHg(Systolic blood pressure) or ≥ 90 mmHg(Diastolic blood pressure) in sitting position at screening time.

7. History of any serious substance or alcohol abuse within one year prior to screening

8. Use of any drugs known to significantly induce or inhibit drug metabolizing enzyme within 30days prior to scheduled study drug administration

9. Cigarette smoking of over 20 sticks per day.

10. Use of any prescription drugs or any over the counter drugs within 10days or quintuple half life(whichever is longer) prior to scheduled study drug administration

11. Donation of whole blood within 2months or any blood products within 1month, prior to scheduled study drug administration

12. Disability to comply with the guidelines written on the protocol

13. Severe acute/chronic medical, physical disorder or laboratory test abnormality that are likely to alter the study result and increase the risk by participating in the study and study drug administration

14. Hypersensitivity to chief component or excipient of Repaglinide

15. History of hypersensitivity to Metformin or Biguanide class of drugs

16. With renal failure or renal inadequacy caused by cardiovascular shock, acute myocardial infarction and sepsis

17. With Congestive heart failure and undergoing drug treatment.

18. Patients undergoing radioactive iodine uptake tests, such as intravenous urography, intravenous cholangiography, angiography, computed tomography using radioactive iodine

19. Patients with type 1 diabetes, acute or chronic metabolic acidosis including diabetic ketoacidosis associated with or without coma

20. With serious infection or trauma

21. Malnutrition, starvation; weakness; pituitary insufficiency or adrenal insufficiency

22. Patients with hepatic failure, pulmonary infarction, serious pulmonary dysfunction, or other conditions associated with hypoxemia, alcohol abuser, or dehydration, diarrhea; vomiting and gastro-intestinal disease

23. Proven to be unsuitable to participate in this clinical study by an investigator

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Dalim BioTech Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Min-Gul Kim, doctor

Role: PRINCIPAL_INVESTIGATOR

Chounbuk National University Hospital

Locations

Chounbuk National University Hospital

Jeonju, Jeollabuk-do, South Korea

Countries

South Korea

Other Identifiers

RM0818-01

Identifier Type: -

Identifier Source: org_study_id